| Specificity |
The product is specific for Omalizumab |
| Host Species |
Mouse |
| Immunogen |
Omalizumab |
| Conjugate |
Unconjugated |
|
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. |
| Application |
Recommended Usage |
| ELISA |
0.005-0.1 µg/ml |
| Competitive ELISA |
10-50 µg/ml |
|
| Form |
Lyophilized |
| Storage Buffer |
This product is lyophilized with PBS, pH 7.2, containing 0.02% sodium azide. |
| Reconstitution |
Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/ml. |
| Storage Instructions |
The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles. |
| Purification |
Protein A affinity column |
| Isotype |
Mouse IgG1,κ |
| Clonality |
Monoclonal |
| Clone ID |
7G11 |
| Note |
GenScript can customize this product per customer's request including product size, buffer components, etc. |
ELISA binding of Anti-Omalizumab Antibody (7G11), mAb, Mouse (GenScript, A02096-40) with Omalizumab. While the antibody does not recognize the human IgG (data not shown).
Coating antigen: Omalizumab, 1 µg/ml.
Anti-Omalizumab Antibody (7G11), mAb, Mouse (GenScript, A02096-40) dilution start from 1,000 ng/ml.
EC50= 28.48 ng/ml.
Anti-Omalizumab Antibody (6C9) (GenScript, A02096-40) blocks Omalizumab binding with Human IgE recombinant protein.
Coating antigen: IgE 0.5 µg/ml.
Omalizumab final concentration: 5 ng/ml.
Anti-Omalizumab antibody dilutions start from 10 μg/ml.
IC50= 0.37 µg/ml.
| Target Background |
Omalizumab with trade name Xolair, is an FDA-approved drug for the treatment of moderate to severe persistent asthma in adults and adolescents (12 years of age and above). It is a recombinant humanized monoclonal antibody. It selectively binds to human immunoglobulin E (IgE). Omalizumab inhibits the binding of IgE to the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils. Anti-Omalizumab Antibody (7G11), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Omalizumab. |
| Synonyms |
Mouse monoclonal to Omalizumab/Xolair |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
